androstane-3,7,17-triol: RN given refers to (3beta,5alpha,7alpha,17beta)-isomer
5alpha-androstane-3beta,7alpha,17beta-triol : A 3beta sterol that is 5alpha-androstane which is substituted by beta-hydroxy groups at positions 3 and 17 and by an alpha-hydroxy group at position 7.
ID Source | ID |
---|---|
PubMed CID | 161274 |
CHEBI ID | 85807 |
MeSH ID | M0065152 |
Synonym |
---|
androstane-3,7,17-triol, (3beta,5alpha,7alpha,17beta)- |
19316-62-2 |
(3s,5r,7r,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,7,17-triol |
5alpha-androstane-3beta,7alpha,17beta-triol |
7269tbu72v , |
unii-7269tbu72v |
3beta,7alpha,17beta-trihydroxy-5alpha-androstane |
androstane-3,7,17-triol |
5a-androstane-3b,7a,17b-triol |
CHEBI:85807 |
(3beta,5alpha,7alpha,17beta)-androstane-3,7,17-triol |
androstane-3,7,17-triol, (3.beta.,5.alpha.,7.alpha.,17.beta.)- |
5.alpha.-androstane-3.beta.,7.alpha.,17.beta.-triol |
5.alpha.-androstan-3.beta.,7.alpha.,17.beta.-triol |
Q27158738 |
DTXSID80940990 |
Role | Description |
---|---|
mammalian metabolite | Any animal metabolite produced during a metabolic reaction in mammals. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
triol | A chemical compound containing three hydroxy groups. |
7alpha-hydroxy steroid | A 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration. |
3beta-sterol | A sterol in which the hydroxy group at position 3 has beta- configuration. |
17beta-hydroxy steroid | A 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (81.82) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.68) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |